




*Changing how the
story ends for
every patient
with a
rare disease*



***The shifting economy and investments in
the life sciences has led to a continuous
cycle of shelving of promising therapeutics
in the rare disease space.***

***...the only constant is the patients and
families***

Odylia Therapeutics

a nonprofit (501c3) drug development company

Mission

Odylia accelerates therapeutic development for rare diseases.

Vision

We are prioritizing a future where drugs are developed for every rare disease based on safety, efficacy, and the available technology, regardless of commercial viability.





Pipeline Programs

Odylia addresses the unmet need to keep moving novel and life-changing rare disease treatments to clinical trials. Odylia is developing the next generation of treatments to transform the lives of rare disease patients.




Brydge Solutions

Odylia leverages our internal scientific and drug development expertise to reduce inefficiencies commonly found on the path from early discovery to clinical trials. We aid partners as they navigate rare disease drug development.

The Odylia Portfolio

We are partnering directly with patients, families, philanthropists, and innovators to ensure there is a path to treatment for those with rare disease.

Odylia's Rare Disease Gene Therapy Pipeline



Our ultimate goal is to bring life altering treatments to people with rare diseases regardless of prevalence or commercial interest. We develop gene therapies through Odylia's pipeline, while bringing this expertise and learnings to the rare disease community through Brydge Solutions.

Accelerating therapeutic development for rare diseases through our pipeline ... or yours



**15+ previous &
ongoing
partnerships since
launching (2021)**

**Diverse diseases
experience:**

- neurodevelopmental
- ocular
- neurodegenerative
- overgrowth disorders
- multi-systemic syndromes





**>90% of
partnerships are
with patient
advocacy groups**

**Therapeutic
modality agnostic,
with extensive
experience in
genetic
technologies**

**Each partnership
tailored to fit the
individual need of the
organization**



Past & Present Brydge Solutions Partners




Program Leads



Ashley Winslow, PhD
CEO & CSO



Kathryn Post DeMott, PhD
Director, Brydge Solutions
Scientist





Jennifer Klein, MS
Director, Operations &
Project Management

Additional expertise added per project needs via in the following areas:

Preclinical gene therapy development, regulatory filing, vector manufacturing, QC/QA and data management, marketing, clinical operations


Odylia partners
with groups
representing
any rare
disorder and has
engaged in
therapeutic
development for
an array of drug
modalities

Brydge Services Overview



Drug Development Pipeline

Preclinical path for patient group funded programs



CSO & R&D Team Services



Innovative Partnerships at a glance



Provided assistance navigating ineffective relationships and initiating new partnerships



Established translational model characterization, analysis, and functionalization



Evaluated therapeutic options, established priorities, and launched drug development efforts



Negotiated drug repurposing, drug screening, and ASO development



Developed plan for novel gene therapy program from initial asset design through clinical trial planning



Designed clinical trials, registry, and natural history study efforts through ongoing KOL and Patient Advisory Board engagement

Landscape Analysis Service



Innovative Partnerships at a glance



Guided drug development including scientific strategy, academic partner discussions, and data interpretation



Feedback impacted fundraising strategy and effectiveness




Enhanced engagement and interest from academic researchers



Expansion of research tool use (i.e. animal models, translational pipeline)




Increased visibility for programs and increased funder confidence



Clinical development, clinical trial design, patient engagement, identified vetted partners

Odylia Brydge Solutions Partnership




Odylia Brydge Pipeline Partnership



Time spent: 9 years
Total investment: \$5M

Time spent: 5 years (to date)
Total investment: <\$1M



Additional Brydge Solutions Initiatives

Odylia believes in the power of sharing information to empower the broader community around us. Through our own drug development experience and our work with partners through Brydge Solutions, we are building a publicly accessible library of resources in hopes that our learnings can help other drug development programs move faster towards the patients that need them. This means Odylia's impact goes beyond the programs we work with directly.

The Odylia Library

Where we provide free resources to help rare disease groups. We also provide links to prior Landscape Analyses and videos.

The Odylia Collective
NOW partnered with



A centralized marketplace to ensure critical resources are findable and accessible for patient groups and other members of the rare disease research community.


***Changing the business model,
changing lives***



This series addresses common questions and roadblocks that face groups as they work to develop therapies.


Meet Comend: software for PAG-led drug development

Research planner




**Organize your
assets & studies.**

CRO marketplace



**Discover and
review partners.**

Organization profiles



**Showcase your
efforts widely.**

What does treatment mean to you?

“less worry, less pain, and more joy!”

“hope, hope for my family and others suffering from rare pediatric diseases”

“prolonging and improving Jordan’s life”

“a treatment keeps Davidson playing baseball”

What does a treatment mean to you?



hope, hope for my family, and others suffering from rare pediatric diseases

jem THERAPEUTICS **Odylia** THERAPEUTICS

What does a treatment mean to you?



a treatment keeps Davidson playing baseball

NPHP Family Foundation **Odylia** THERAPEUTICS

What does a treatment mean to you?



less worry, less pain, and more joy!

Smith-Kingsmore SYNDROME FOUNDATION **Odylia** THERAPEUTICS

What does a treatment mean to you?



prolonging and improving Jordan’s life

Saving Jordan Avi Ogman Foundation **Odylia** THERAPEUTICS
Research & Development of Cures for TECPR2 Genetic Disease

Odylia THERAPEUTICS

Thank You



Contact Us

✉ info@odylia.org

🌐 www.odylia.org

📷 Odylia Therapeutics

🌐 Odylia Therapeutics


✉ Ashley Winslow
awinslow@Odylia.org

Partner Testimonials



Mike Kaplan, MD
President & CEO, JEM Therapeutics

Our goal is to accelerate progress as quickly as possible so we sought a partner who had the depth of expertise to provide guidance on scientific strategy, but who could also give us insights into the financial and operational aspects of our company's growth. But what really stood out about Odylia was their accessibility and personal touch. They are as committed as we are to rare disease patients and that's a quality that we highly value and is critical to our success.



Kristen Davis
Executive Director, CLOVES Syndrome Community

Having a child with a rare disease means needing to become an expert in drug development. But there are so many roadblocks and things to learn. Our partnership with Odylia's Brydge Solutions helped us better understand the science of CLOVES Syndrome and gave us a fresh perspective on therapeutic options and potential collaborators for the future.



Allison Kaczinski
President, SATB2 Gene Foundation

Odylia, through Brydge Solutions, really helped the SATB2 Gene Foundation focus and start moving in the direction we need to be moving in. Their landscape analysis broke everything down into workable goals in language that could be shared with our communities.